Supplementary Appendix：

**Table S1** Absolute effects on cardiovascular events in each therapeutic regimen

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | High-dose statins | | PCSK9 inhibitors plus high-dose statins | Ezetimibe plus high-dose statins | PCSK9 inhibitors plus ezetimibe plus high-dose statins |
| All-cause mortality | | 0.032 | 0.03 | 0.032 | 0.03 |
| Cardiovascular mortality | | 0.019 | 0.018 | 0.018 | 0.017 |
| Nonfatal myocardial infarction | | 0.084 | 0.068 | 0.073 | 0.059 |
| Nonfatal stroke | | 0.08 | 0.059 | 0.066 | 0.048 |
| All-cause mortality | | 0.032 | 0.03 | 0.032 | 0.03 |
| Cardiovascular mortality | | 0.019 | 0.018 | 0.018 | 0.017 |
| Nonfatal myocardial infarction | | 0.084 | 0.068 | 0.073 | 0.059 |

**Table S2** Summary of probabilistic distributions applied in the model

|  |  |  |
| --- | --- | --- |
| Parameter cluster | Parameters | Distribution |
| Clinical data | Relative risk | Normal distribution |
| Cost data | Annual costs of each drug, cost of cardiovascular events | Lognormal distribution |
| Utility data | Utility weights assigned to each state | Beta distribution |

**Table S3** The keywords for relevant parameters in the Markov model

|  |  |  |  |
| --- | --- | --- | --- |
| Date | Database | Keywords | Comments |
| May 1,2022 | PubMed  EMBase  Scopus | Cardiovascular disease  AND  (Cost-effective\* OR economic evaluation)  AND  China | CVD cost in China |
| May 5,2022 | PubMed  EMBase  Scopus | (Utility OR Quality of life)  and  Cardiovascular disease | Utility of CVD |